Database

Startups

Main Industry
Biotechnology
Main Product/Service
Our Universal Antibody Lock™ is an innovative proprietary platform designed to generate conditionally-activated antibody therapeutics for various antibody formats, including monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. This technology enhances antibody selectivity while reducing on-target toxicity, providing safer and more effective treatment solutions for patients.
Founded Year
2021
Unified Business No.
90663465
Status
Active
Number of Employees
0
Total Paid-in Capital
69,100,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
PrecisemAb Biotech develops next-generation biologics using its Universal Antibody Lock™ technology, which keeps therapeutic antibodies inactive in healthy tissues and activates them only at disease sites. This tumor-selective approach reduces off-target effects and systemic toxicity while improving treatment efficacy. Backed by strong scientific expertise, the company focuses on designing safer and more precise antibody therapeutics to advance targeted cancer treatment.



More ↓

Similar Companies